2023
Implementation of a Best Practice Advisory to Improve Infection Screening Prior to New Prescriptions of Biologics and Targeted Synthetic Drugs
Baker H, Fine R, Suter F, Allore H, Hsiao B, Chowdhary V, Lavelle E, Chen P, Hintz R, Suter L, Danve A. Implementation of a Best Practice Advisory to Improve Infection Screening Prior to New Prescriptions of Biologics and Targeted Synthetic Drugs. Arthritis Care & Research 2023 PMID: 37382043, DOI: 10.1002/acr.25181.Peer-Reviewed Original ResearchBest practice advisoryHepatitis B virusAutoimmune rheumatic diseasesBPA implementationSynthetic disease-modifying antirheumatic drugsDisease-modifying antirheumatic drugsHepatitis C virus infectionHepatitis B surface antigenC virus infectionUse of biologicsB surface antigenQuality improvement initiativesElectronic health recordsEligible patientsAntirheumatic drugsRheumatic diseasesRheumatology practiceSociety guidelinesB virusPractice advisoryComputerized decision support systemVirus infectionRoutine screeningPatient screeningPatients
2022
Concurrent use of tumor necrosis factor inhibitor and tyrosine kinase inhibitor in ankylosing spondylitis and myeloid neoplasm
Gupta A, Department of Medicine Y, Afinogenova Y, Podoltsev N, Danve A, Section of Rheumatology A, Section of Hematology D. Concurrent use of tumor necrosis factor inhibitor and tyrosine kinase inhibitor in ankylosing spondylitis and myeloid neoplasm. European Journal Of Rheumatology 2022, 9: 215-216. PMID: 35156633, DOI: 10.5152/eurjrheum.2022.21097.Peer-Reviewed Case Reports and Technical NotesMyeloid neoplasmsBiologic disease-modifying agentsTumor necrosis factor inhibitorsTyrosine kinase inhibitor imatinibNecrosis factor inhibitorsAutoimmune rheumatic diseasesDisease-modifying agentsKinase inhibitor imatinibTyrosine kinase inhibitorsMiddle-aged malesRheumatic diseasesFactor inhibitorsPatients' qualityFavorable outcomeHematologic malignanciesInhibitor imatinibBeta rearrangementInfliximabConcurrent useKinase inhibitorsCancer diagnosisPatientsNeoplasmsAppropriate casesInhibitors
2020
Managing rheumatic diseases during COVID-19
Ladani AP, Loganathan M, Danve A. Managing rheumatic diseases during COVID-19. Clinical Rheumatology 2020, 39: 3245-3254. PMID: 32895747, PMCID: PMC7476772, DOI: 10.1007/s10067-020-05387-8.Peer-Reviewed Original ResearchConceptsAutoimmune rheumatic diseasesRheumatic diseasesImmunosuppressive agentsRheumatology practiceCOVID-19Multisystem autoimmune rheumatic diseaseLong-term complicationsCOVID-19 patientsCoronavirus disease 2019 (COVID-19) pandemicCOVID-19 infectionDisease 2019 pandemicMode of spreadImmunosuppressant managementImmunosuppressant medicationsViral illnessOrgan failureClinical featuresAutoimmune diseasesSerious infectionsTreatment optionsEffective vaccineImmune systemMedicationsDiseasePatients